Company / Return on Assets (ROA)
Corvus Pharmaceuticals, Inc. Return on Assets (ROA) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-90.4%
FY2024
5-year range
-90.4% / -7.0%
FY2020-FY2024
Trend
-52.3%
vs FY2023
Sector context
#203 of 213
Health Care
What the data says
Among 213 Health Care companies, Corvus Pharmaceuticals, Inc. is in the bottom 5% for return on assets (roa). Return on Assets (ROA) has fluctuated over the past 10 years, ranging from -90.4% in FY2024 to -7.0% in FY2020.
Based on SEC 10-K filings.
-90.4% in FY2024 with a 5-year CAGR of -34.6%.
Declined from -60.5% to -90.4% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -50.9pp
- 5-Year Change
- -34.6pp
- 10-Year Change
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 213This company -90.4% Sector average -24.1%
▼
-275.8% below sector average
Key checks
Key Insights
- In FY2024, return on assets (roa) decreased 52.3% year-over-year.
- Currently 66.3pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -90.4% | -52.3% |
| FY2023 | -59.3% | +2.0% |
| FY2022 | -60.5% | -53.2% |
| FY2021 | -39.5% | -463.6% |
| FY2020 | -7.0% | +87.4% |
| FY2019 | -55.8% | -40.6% |
| FY2018 | -39.7% | +32.4% |
| FY2017 | -58.7% | -126.3% |
| FY2016 | -25.9% | +18.5% |
| FY2015 | -31.8% | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026